GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Change In Inventory

NKGen Biotech (NKGen Biotech) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Change In Inventory?

NKGen Biotech's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means NKGen Biotech's inventory stayed the same from Dec. 2023 to Mar. 2024 .

NKGen Biotech's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means NKGen Biotech's inventory stayed the same from Dec. 2022 to Dec. 2023 .

NKGen Biotech's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


NKGen Biotech Change In Inventory Historical Data

The historical data trend for NKGen Biotech's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Change In Inventory Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Change In Inventory
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Change In Inventory Get a 7-Day Free Trial - - - - -

NKGen Biotech Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech  (NAS:NKGN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NKGen Biotech's Days Inventory for the quarter that ended in is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

NKGen Biotech's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

NKGen Biotech's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech Change In Inventory Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.